RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Conference Call and Webcast Information:

Date: Wednesday, August 7, 2024 at 4:30 PM ET

Participant Dial-in (US): 1-800-717-1738

Participant Dial-in (International): 1-646-307-1865

Conference: 39584

Webcast Access:

The conference call utilizes the “Call me™” technology

  • Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link, above, for instant telephone access to the event.
  • Call me™ link will be made active 15 minutes prior to scheduled start time.

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at .

Investor Contact:

Tim McCarthy

LifeSci Advisors



EN
05/08/2024

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Listing Rule”). To regain compliance...

September 16, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Issues Mid-Year CEO Letter to Shareholders CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a truly transformational year for Relmada Therapeutics. With the year now well into its second half, I am pleased to share an update on our recent progress and to thank you f...

September 10, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC 6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 P...

August 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results o...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Dat...

July 31, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan...

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch